The retinoid anticancer signal: mechanisms of target gene regulation by Liu, T et al.
The retinoid anticancer signal: mechanisms of target gene
regulation
T Liu
1, A Bohlken
1, S Kuljaca
1, M Lee
1, T Nguyen
1, S Smith
1, B Cheung
1, MD Norris
1, M Haber
1, AJ Holloway
2,
DDL Bowtell
2 and GM Marshall*,1,3
1Children’s Cancer Institute Australia for Medical Research, Randwick NSW 2031, Australia;
2Peter MacCallum Cancer Centre, East Melbourne VIC
8006, Australia;
3Centre for Children’s Cancer and Blood Disorders, Sydney Children’s Hospital, High Street, Randwick NSW 2031, Australia
Retinoids induce growth arrest, differentiation, and cell death in many cancer cell types. One factor determining the sensitivity or
resistance to the retinoid anticancer signal is the transcriptional response of retinoid-regulated target genes in cancer cells. We used
cDNA microarray to identify 31 retinoid-regulated target genes shared by two retinoid-sensitive neuroblastoma cell lines, and then
sought to determine the relevance of the target gene responses to the retinoid anticancer signal. The pattern of retinoid
responsiveness for six of 13 target genes (RARb2, CYP26A1, CRBP1, RGS16, DUSP6, EGR1) correlated with phenotypic retinoid
sensitivity, across a panel of retinoid-sensitive or -resistant lung and breast cancer cell lines. Retinoid treatment of MYCN transgenic
mice bearing neuroblastoma altered the expression of five of nine target genes examined (RARb2, CYP26A1, CRBP1, DUSP6,
PLAT) in neuroblastoma tumour tissue in vivo. In retinoid-sensitive neuroblastoma, lung and breast cancer cell lines, direct inhibition of
retinoid-induced RARb2 expression blocked induction of only one of eight retinoid target genes (CYP26A1). DNA demethylation,
histone acetylation, and exogenous overexpression of RARb2 partially restored retinoid-responsive CYP26A1 expression in
RA-resistant MDA-MB-231 breast, but not SK-MES-1 lung, cancer cells. Combined, rather than individual, inhibition of DUSP6 and
RGS16 was required to block retinoid-induced growth inhibition in neuroblastoma cells, through phosphorylation of extracellular-
signal-regulated kinase. In conclusion, sensitivity to the retinoid anticancer signal is determined in part by the transcriptional response
of key retinoid-regulated target genes, such as RARb2, DUSP6, and RGS16.
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Retinoids, including retinoic acid (RA), regulate the expression of
genes involved in cell proliferation, differentiation, and apoptosis,
and are essential for normal embryonic development and health in
the adult (Evans and Kaye, 1999). The multiple phenotypic effects
of retinoids are mediated, in part, by a classical pathway involving
two classes of nuclear receptors: retinoic acid receptors (RARs)
and retinoid X receptors (Chambon, 1996). The transcriptional
activation, which follows liganded RAR binding to a RA responsive
element (RARE), triggers retinoid target gene expression or
suppression, and subsequent specific biological effects. In addition
to the classical nuclear RA signalling mechanism, covalent binding
of RA or RAR to other cellular macromolecules may exert other
retinoid effects (Altucci and Gronemeyer, 2001; Balmer and
Blomhoff, 2002).
Disruption of normal retinoid signalling has been causally
linked to the genesis of several human and experimental cancers
(reviewed in (Sun and Lotan, 2002)). Defined mechanisms of
retinoid resistance in cancer cells have included increased retinoid
catabolism, reduced expression of nuclear retinoid receptors, and
repressed transcriptional response of RA target genes (Freemantle
et al, 2003).
Following retinoid treatment in vitro, many cell types upregulate
the expression of target genes coding for proteins involved in
retinoid binding and metabolism, such as the nuclear RARb2 and
retinoic acid hydroxylase (CYP26A1) (Sonneveld et al, 1998;
Cheung et al, 2003). The RA-responsive transcription of RARb2i s
frequently lost in breast, lung, prostate, cervical, and oral
carcinoma (Sun and Lotan, 2002; Freemantle et al, 2003). We
have previously shown that derepression, or exogenous over-
expression, of RARb2 can restore retinoid responsiveness of some
cells (Cheung et al, 2003). We, and others, have also provided
evidence that unliganded RARb2 may have an additional role as
a tumour suppressor gene (Houle et al, 1993; Cheung et al, 1998).
However, target genes of liganded or unliganded RARb2 have
not yet been defined. CYP26A1, on the other hand, leads to RA
catabolism.
Here, we have defined a group of 31 RA-regulated genes in
RA-responsive neuroblastoma cells in vitro. A subset of these
target genes was also regulated in vivo, and correlated with
phenotypic retinoid sensitivity in lung and breast cancer cells
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sin vitro. RA-induced expression of liganded RARb2 directly
regulated CYP26A1 in RA-sensitive and -resistant neuroblastoma,
lung and breast cancer cells. Promoter methylation and histone
deacetylation, in part, explained the lack of retinoid responsive-
ness of target genes in some RA-resistant cells. Synchronous
induction by RA of two target genes, known to be mitogen-
activated protein kinase (MAPK) extracellular-signal-regulated
kinase (ERK) signaling pathway inhibitors, was required to
mediate retinoid effects on cell proliferation, through reduction
of ERK phosphorylation.
MATERIALS AND METHODS
Cell culture
Human neuroblastoma BE(2)-C and SH-SY5Y cell lines were
generously supplied by Dr J Biedler (Memorial Sloan-Kettering
Cancer Center, NY, USA). Human lung Calu-6 and SK-MES-1, and
mammary T47D and MDA-MB-231 epithelial cancer cells were
obtained from the American Type Culture Collection (Manassas,
VA, USA). All cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with L-glutamine and 10% fetal calf serum.
(aRA) all-trans RA, 13-cis-RA, trichostatin A (TSA, an inhibitor of
histone deacetylase) (Sigma, St Louis, MO, USA) were solubilised
in ethanol. The DNA demethylation agent aza-CdR (5-aza-2-
deoxycytidine) (Sigma) was dissolved in water.
cDNA microarray
After treatment with control or 10mM aRA for 1, 24h, 3 or 7 days,
BE(2)-C and SH-SY5Y cells were lysed, and RNA extracted with the
standard guanidinium/phenol/chloroform method. Direct labelling
cDNA microarray experiments were carried out as described
previously (Boussioutas et al, 2003). Results from three indepen-
dent microarray hybridisations, with probes synthesised using
RNA from three independent cell treatment experiments, were
analysed. An arbitrary postnormalisation cutoff of two-fold up- or
downregulation was used to define significant differential gene
expression.
Semiquantitative competitive reverse transcription–
polymerase chain reaction (RT–PCR)
Confirmation of microarray data in the two neuroblastoma cell
lines, in mammary and lung cancer cell lines, and in neuroblas-
toma tissues was carried out with competitive RT–PCR with RNAs
from three independent cell culture experiments and from 12 mice.
All results of RT–PCR for each gene were analysed from at least
three PCR results. The competitive PCR techniques have been
previously described (Norris et al, 1996; Cheung et al, 2003), which
involved determining a ratio between the level of expression of a
target gene and that of the house-keeping gene b2-microglobulin
(b2M) in total RNA samples. Fold induction of a target gene by RA
was calculated by ascribing the ratio as 1.0 for control-treated
samples. Specific primers are listed in Table 1.
Small interfering RNA (siRNA) designing
Small interfering RNA for RARb2 was purchased from Dharmacon
(Dharmacon Research, Lafayette, CO, USA) (Catalogue number:
M003438-00-05). The sequences of the siRNA were patented
and cannot be published according to Dharmacon. Small inter-
fering RNA target sequences of 21 nucleotides for DUSP6
and RGS16 were identified using the principles described by
Elbashir et al (2001). Three suitable targets were found for DUSP6:
AAGAACTGTGGTGTCTTGGTA, AAGCTCAATCTGTCGATGAAC,
and AAGTGCGGAATTGGTTAATAC; and three targets for RGS16:
AAGATCCGATCAGCTACCAAG, AAACTTCTCAGAAGATGTGCT,
and AACAAGGCAGAAAAGGATCCT. Double-stranded siRNA
oligos were in vitro transcribed with Ambion Silencer siRNA
Construction Kit (Ambion, Austin, TX, USA) according to the
manufacturers’ instructions. Scrambled siRNAs with the same
GCAT content as target siRNAs, but different sequences, were also
in vitro transcribed, and it was confirmed that all siRNAs did not
resemble any other mRNA (o15/21).
Transient transfection
Plasmid cDNA RARb2 and control plasmids were kindly
provided by Professor P Chambon (INSERM, Strasbourg, France).
Table 1 Primers for semiquantitative competitive RT–PCR for human (Hs) cell lines and mouse (Mm) tissues
Gene Forward primer Reverse primer
b2M (Hs) ACCCCCACTGAAAAAGATGA ATCTTCAAACCTCCATGATG
RARb2 (Hs) CTACACTGCGAGTCCGTCTT CAGAGCTGGTGCTCTGTGTT
CYP26A1 (Hs) CAGCCACATCTCTGATCACT AAGTTGTTCCAAAATTTCCA
CRBP1 (Hs) AGGCATAGATGACCGCAAGT TCATCTCTAGGTGCAGCTCA
CRABP1 (Hs) GATCCACTGCACCCAAACTC AAGCCAGCTGCCTTCATTCC
RGS16 (Hs) GTGGGGCAGTAAACACAGCA GAACTCCAGGTTCTCCTCAC
DUSP6 (Hs) GTTTTTCCCTGAGGCCATTT TAGGCATCGTTCATCGACAG
TIA1 (Hs) AAGGATTTGGAGTAGATCAA AGTCCCGGCTCACTGTGTTT
RET (Hs) GGAAAAGTGGTCAAGGCAAC ATGTGGGTGGTTGACCTGCT
FLNB (Hs) AGAGCATCACCCGCACCAGT GCACAATCTCTGCCTCAGTC
EGR1 (Hs) CAGCAGCAGCAGCACCTTCA CGATGTGTTTGGCTGGGGTA
PLAT (Hs) AGGGCTGGAGAGAAAACCTC CGAAACGAAGACTGCTCCAC
SMAD3 (Hs) GTGACCACCAGATGAACCAC GTAGTAGGAGATGGAGCACC
DLK1 (Hs) GTCCCCTTTGTGACCAGTGC GAGGAGCAGGCCCGAACATC
b2M (Mm) TGGTGCTTGTCTCACTGACC CGGGTGGAACTGTGTTACG
RARb2 (Mm) ACAAGTCATCGGGCTACCAC CAGTACTGGCATCGGTTCCT
CYP26A1 (Mm) ACCCACATGTCCTCCAGAAA AGGATTCAATCGCAGGGTCT
CRBP1 (Mm) GGACTTCAACGGGTACTGGA AGTTGGCGATTTTGCGTAAG
DUSP6 (Mm) AGTTTTTCCCTGAGGCCATT CATCGTTCATGGACAGGTTG
PLAT (Mm) ACTCAGTGCCTGTCCGAAGT GCACTGGCAGACAAAGTCAG
RGS16 (Mm) GCTCCGATACTGGGGGTATT CGTCTTTAGGAAGGCATGGA
FLNB (Mm) CCCAAACTCAACCCAAAGAA CCTTCTGGGTCCTCAACAAA
EGR1 (Mm) GAGCGAACAACCCTATGAGC GGGATAACTCGTCTCCACCA
RET (Mm) ACAAGAGGCCAGTGTTTGCT GTGAGTCCGAAGGTGTGGAT
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sTransient transfection was performed using Superfect transfection
reagent (Qiagen, Clifton Hill, Victoria, Australia) in MDA-MB-231
and SK-MES-1 cells, or Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) in SH-SY5Y cells. After 8h, cells were treated
with 10mM aRA or control. Transfection efficiency and its effect on
potential target gene expression were assessed by RT–PCR with
RNA extracted 24h or 3 days after aRA treatment.
Small interfering RNA SH-SY5Y, Calu-6, and T47D cells were
transfected with 100nM siRNA using Lipofectamine 2000 reagent
according to Invitrogen. After 8h, cells were treated with 10mM
aRA or control. RNA and/or protein were extracted 48h later.
Transfection efficiency and its effect on potential target gene
expression was assessed by RT–PCR and/or immunoblot.
Immunoblot analysis
Cells were lysed, and protein extracted and analysed by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis. For DUSP6
and RGS16 studies, membranes were probed with either rabbit
anti-RGS16 antibody (diluted 1:500) or goat anti-DUSP6 antibody
(1:500) (Santa Cruz Biotechnology, CA, USA) followed by
horseradish peroxidase (HRP)-conjugated anti-rabbit (1:2000)
or anti-goat antiserum (1:2000) (Pierce, Rockford, IL, USA),
respectively. The membranes were then incubated with fluores-
cence-conjugated ECL Plus (Amersham) and scanned with a
Typhoon Scanner (Amersham). Membranes were lastly reprobed
with anti-b-actin antibody (Pierce) as a loading control. Compara-
tive protein expression was semiquantified by analysing target
protein bands vs b-actin with ImageQuant software (Amersham).
For the MAPK ERK phosphorylation study, membranes were
probed with mouse antiphosphorylated ERK1/2 antiserum
(1:2000) (Upstate Biotech, MA, USA), followed by incubation
with HRP-conjugated anti-mouse antiserum (1:2000) (Pierce).
Equal loading of protein was confirmed by probing the membranes
for total ERK protein with rabbit anti-ERK1/2 (nonphosphory-
lated) antiserum (1:2000) (Upstate Biotech), followed by incuba-
tion with HRP-conjugated anti-rabbit antiserum (1:2000) (Pierce).
Cell proliferation assay
The cell proliferation assay was carried out with the In Situ Cell
Proliferation Kit, FLUOS (Roche Applied Science, Switzland),
according to the manufacturer’s instructions. SH-SY5Y cells
transfected with scrambled siRNA, DUSP6 siRNA, RGS16 siRNA,
a combination of DUSP6 and RGS16 siRNAs, or a combination of
scrambled siRNAs, were treated with 10mM aRA for 64h, followed
by incubation with 10mM 5-bromo-20-deoxyuridine (BrdU) for
45min. After fixation in 70% ethanol overnight and denaturation
with hydrochloric acid, cells were incubated with an anti-BrdU-
FLUOS antibody and analysed on a flow cytometer (FACScan,
Becton Dickinson, NJ, USA). Cells incubated with solvent instead
of BrdU, but incubated with anti-BrdU-FLUOS were used as
control for autofluorescence and background staining. Low and
high fluorescence regions were defined for quantitation: low
fluorescent regions comprised 495% of control cells (BrdU-
negative or nonproliferating cells), whereas high fluorescent
regions contained proliferating BrdU-positive cells. The percentage
of BrdU-negative and -positive cells over total cell population was
compared among target gene siRNA-, and scrambled siRNA-
transfected cells treated with 10mM aRA.
Animal model studies
The generation of the MYCN transgenic mice has been described
previously (Weiss et al, 1997). All homozygote MYCN transgenic
mice developed neuroblastoma at the age of 6–7 weeks (Weiss
et al, 1997). Once a tumour was palpable in the abdomen,
homozygote MYCN transgenic mice were randomised and treated
with either solvent control (n¼6) or 13-cis-RA at the dosages of
0.72–1.43mmol24h
 1 (n¼6) via an Alzet micro-osmotic pump
(ALZET, Cupertino, CA, USA). The pump was surgically implanted
subcutaneously at the back, which caused minimal discomfort
to the mice (Burkhart et al, 2003). The drugs were delivered at a
constant rate of 0.5mLh
 1 (Burkhart et al, 2003). Mice were
monitored once every day from the commencement of treatment
and killed 5 days after treatment. Tumour tissues were removed
and RNA was extracted. Competitive RT–PCR was carried out
to examine whether RA target genes identified in vitro were
modulated by RA in vivo as well. All animal experimental
procedures were approved by the University of New South Wales
Animal Care and Ethics Committee, and were consistent with
United Kingdom Coordinating Committee on Cancer Research
guidelines for the welfare of animals in experimental neoplasia.
Compared with untreated animals and animals treated with
control, 13-cis-RA treatment did not induce any significant side
effects.
Statistical analysis
All data for statistical analysis were calculated as mean7standard
error. Differences were analysed for significance using ANOVA
among groups. A probability value of 0.05 or less was considered
significant.
RESULTS
Microarray data and validation of a subset of differentially
expressed RA target genes
To identify RA-regulated target genes in neuroblastoma cells, we
performed triplicate microarray experiments comparing gene
expression in BE(2)-C and SH-SY5Y neuroblastoma cell lines
treated continuously with 10mM aRA for 1, 24h, 3 or 7 days.
SH-SY5Y cell line is nonamplified, and the BE(2)-C cell line is
amplified, for the oncogene MYCN, an important determinant of
the RA response in vitro and patient prognosis in vivo (Bordow
et al, 1998; Nguyen et al, 2003).
Microarray slides with 4500 cDNA clones, representing pre-
dominantly genes with known functions, were hybridised with
cDNA from aRA- or control-treated cells. In total, 31 genes were
up- or downregulated by X2-fold by aRA in both cell lines, at one
or more time points in triplicate (Po0.05) (listed in Table 2
according to the time course of changes in gene modification).
This list of RA-regulated targets included genes coding for proteins
known to be involved in: (i) retinoid binding and metabolism
(RARb2, cellular retinoid-binding protein 1 (CRBP1), and
CYP26A1); (ii) the MAPK signalling pathway (regulator of G-protein
signalling 16 (RGS16) and dual specificity phosphatase 6
(DUSP6)); (iii) cell structure and differentiation (filamin B (FLNB),
c-RET proto-oncogene (RET), a polypeptide Cu
2þ transporting
ATPase (ATP7A), and d-like 1 homolog (Drosophila) (DLK1)); and
(iv) angiogenesis or cancer invasion (early growth response
protein 1 (EGR1) and tissue plasminogen activator (PLAT)).
Among the 31 genes, a classical RARE could be found in the
promoter region of RARb2, CYP26A1, CRBP1 and PLAT
(Chambon, 1996; Sun and Lotan, 2002). While RGS16 expression
was upregulated at 1h after aRA (Table 2, Figure 1A), all other RA
target genes showed a more gradual change in expression at 1, 3,
and 7 days after commencement of aRA. Only four of 31 target
genes demonstrated downregulated expression patterns after aRA
treatment. In addition to those genes listed in Table 2, a further 21
genes exhibited X2-fold change in expression in only one of
the two neuroblastoma cell lines (data not shown). To validate
the microarray data, semiquantitative, competitive RT–PCR was
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two cell lines (Table 2). The results of RT–PCR were consistent
with the microarray data in 10 out of 11 genes, with TIA1 as the
only exception. Examples of the RT–PCR results were shown in
Figure 1A.
We next examined whether target gene responses were specific
for aRA, compared with other isomeric retinoid compounds, such
as 13-cis-RA, which is in current clinical use in neuroblastoma
patients (Matthay et al, 1999). Competitive RT–PCR analysis
confirmed that all eight target genes tested were upregulated by
13-cis-RA in a manner similar to aRA in BE(2)-C cells (Figure 1B).
More specifically, RARb2, CYP26A1, CRBP1, RGS16, DUSP6,
FLNB, PLAT, and RET were upregulated by 5.0-, 107.1-, 1.7-,
1.8-, 1.9-, 4.5-, 2.6-, and 1.6-fold, respectively, 3 days after 10mM
13-cis-RA treatment (Po0.05 in all cases).
Regulation of RA target genes in neuroblastoma tumour
tissue in vivo
To assess whether the RA target genes identified in vitro were also
modulated by RA in vivo, we treated homozygous MYCN
transgenic mice with palpable abdominal neuroblastoma with
13-cis-RA (0.72–1.43mmol24h
 1) or solvent control, and com-
pared target gene expression by RT–PCR (Figure 1C). While no
significant side effects were observed, the 5-day therapy with
13-cis-RA did not reduce tumour size, when compared with
solvent-treated mice. Competitive RT–PCR showed that 13-cis-RA
upregulated the expression of RARb2 by 7.670.8-fold, which was
comparable to the in vitro data. In contrast, CYP26A1 was induced
by only 2.070.3-fold (Po0.05), compared to induction by more
than 100-fold in 13-cis-RA-treated BE(2)-C cells in vitro. Other RA
target genes which were also upregulated in vivo included CRBP1
by 1.870.1-fold, DUSP6 by 2.570.5-fold, and PLAT by 1.970.2-
fold (Po0.05). However, 13-cis-RA did not significantly modulate
RET, RGS16, FLNB, and EGR1 expression in the tissue samples
from tumour-bearing animals treated for 5 days.
Retinoid responsiveness of specific RA target genes
correlates with the phenotypic retinoid response in
neuroblastoma, lung and breast cancer cells
We next asked whether the patterns of change in RA target gene
expression seen in neuroblastoma cells were shared by other
cancer types. RA-sensitive lung (Calu6) and breast (T47D) cancer
cell lines, and RA-resistant lung (SK-MES-1) and breast (MDA-
MB-231) cancer cells were treated with control or 10mM aRA for 1,
24h, 3 or 7 days. Competitive RT–PCR was carried out to assess
changes in the expression of the 13 target genes with cDNA from
three independent cell culture and treatment experiments. As
shown in Table 3 and Figure 1A and D, four of 12 target genes
(RARb2, CYP26A1, CRBP1, and RGS16) were upregulated by more
than two-fold in both the RA-sensitive lung and breast cancer cells.
However, RGS16, RARb2, and CYP26A1 were not detectable and
not RA inducible in both of the RA-resistant breast and lung
cancer cells. DUSP6 was induced in T47D cells only, while EGR1
was upregulated in Calu6 cells only. Surprisingly, RET and PLAT
were downregulated by 10- and 2.2-fold in RA-sensitive Calu-6
lung cancer cells, whereas both target genes were upregulated in
both neuroblastoma cell lines. In contrast, ATP7A, DLK1, CRBP1,
and SMAD3 were not modulated by aRA in RA-sensitive lung and
breast cancer cells.
Table 2 Comparison of target gene fold induction by aRA between microarray data (outside parenthesis) and competitive RT–PCR results (inside
parenthesis) in neuroblastoma cells treated with 10mM aRA
SH-SY5Y BE(2)-C
Gene description GeneBank accession 1h 24h 3 days 7 days 1h 24h 3 days 7 days
RGS16 AA453774 2.0 (2.4) 4.0 (4.1) 3.0 (2.9) 2.2 (1.9) 1.7 (1.9) 2.9 (3.2) 1.9 (2.6) 1.7 (1.9)
TIA1 N59426 0.2 (0.9) 0.1 (0.8) 0.2 (0.9) 0.2 (0.9) 0.6 (1.2) 0.6 (0.7) 0.6 (0.8) 0.5 (0.6)
RARb2 AA419238 0.9 0.9 1.5 2.6 3.1 4.0 4.0 5.4
CYP26A1 R51021 1.1 (—) 11 (91) 11 (100) 17 (94) 0.8 (—) 1.5 (36) 3.3 (87) 7.3 (94)
CRBP1 AA700832 1.2 (1.0) 2.2 (1.9) 3.0 (1.7) 3.2 (1.6) 0.8 (1.2) 2.0 (1.6) 2.9 (2.8) 3.6 (2.3)
CRABP1 AA454702 1.1 2.6 2.4 4.3 1.0 1.2 2.2 5.1
ATP7A AA236141 1.0 (1.7) 2.0 (2.6) 4.5 (4.2) 7.2 (3.9) 1.0 (1.1) 2.1 (4.6) 3.9 (16) 6.3 (23)
IL13RA2 R52796 1.1 1.2 1.7 5.1 1.0 2.0 2.0 3.2
DUSP6 AA630374 1.2 3.0 5.5 5.5 0.8 3.5 6.7 5.9
EGR1 AA486533 1.0 (1.0) 2.4 (3.4) 2.6 (1.3) 3.4 (1.3) 1.4 (0.3) 2.6 (1.2) 2.0 (1.3) 1.9 (1.5)
RET H24956 1.2 (0.9) 3.3 (2.7) 4.0 (2.3) 4.0 (1.8) 1.2 (0.7) 2.5 (1.4) 2.9 (2.7) 2.3 (2.1)
PLAT AA447797 0.9 (1.4) 3.1 (1.5) 3.3 (1.8) 17 (2.0) 1.0 (1.4) 2.0 (1.9) 3.9 (2.3) 6.1 (2.4)
FLNB AA486239 1.1 (1.2) 2.1 (5.2) 3.2 (4.2) 8.5 (6.0) 1.2 (0.7) 3.7 (2.0) 4.3 (2.5) 10 (3.2)
ITGA1 H68922 1.1 2.4 3.4 6.5 0.9 2.4 3.5 3.7
TMSB4X AA634103 1.3 2.3 3.7 8.3 1.0 1.4 3.4 4.5
HOXD9 AA424871 1.2 2.0 2.5 3.4 1.1 1.5 1.7 2.0
CNN2 AA284856 1.2 2.2 1.9 3.5 0.9 1.0 1.6 2.1
TRB2 AA458653 1.3 2.2 4.0 6.3 1.3 1.8 2.7 3.4
CXCR4 AA621824 1.1 0.5 0.4 0.4 1.0 1.0 0.5 0.5
TM4SF3 AA045699 1.1 1.3 2.8 3.8 1.2 1.1 2.7 6.0
DCX AA620421 1.0 1.1 2.9 3.1 1.1 1.3 3.8 3.4
ASL AA486741 1.1 1.9 3.0 3.2 1.1 1.8 2.9 2.5
DCN AA099394 1.1 1.3 2.6 2.5 1.1 1.1 1.9 2.8
TP53I3 AA668595 1.1 1.1 1.6 3.0 1.2 1.4 2.9 5.1
IGFBP3 AA598601 1.1 0.5 0.8 3.2 0.9 0.9 2.4 4.6
AF1Q AA456008 1.3 1.7 2.8 3.4 1.2 1.5 1.9 2.8
DLK1 AA576129 1.5 (0.9) 0.6 (0.7) 0.5 (0.6) 0.2 (0.4) 1.0 (1.1) 1.2 (1.0) 0.3 (0.7) 0.1 (0.5)
SGNE1 AA670429 1.1 1.1 1.5 3.1 0.9 1.0 1.7 2.7
PTN AA001449 1.2 1.0 1.5 2.9 1.0 1.2 1.8 2.5
SMAD3 W72201 1.1 (1.2) 1.2 (2.7) 1.8 (2.1) 3.1 (2.1) 0.9 (1.1) 1.4 (1.4) 1.6 (1.7) 3.0 (2.7)
PTPRU AA644448 1.2 0.7 0.6 0.5 1.2 0.7 0.6 0.4
(—) represents undetectable by PCR.
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restore RARb2 and CYP26A1 gene expression in
RA-resistant breast, but not lung cancer cells
We observed a close correlation between the expression pattern of
RARb2 and CYP26A1 in response to retinoid (Tables 2 and 3). This
led us to hypothesise that these two target genes may have a
common mechanism of transcriptional repression in RA-resistant
cells. To determine whether DNA methylation of regulatory
elements resulted in the repression of RARb2 and CYP26A1,
RA-resistant lung and breast cancer cells were treated with the
demethylating agent, aza-CdR. Treatment of cells with 0.1, 1.0, and
10mM aza-CdR, in combination with 10mM aRA for 3 days, did not
restore RARb2 and CYP26A1 expression in the aRA-resistant cells
when analysed by competitive RT–PCR. Minimally expressed
genes may be out-competed by the b2M gene in a competitive
RT–PCR (Freeman et al, 1999). Therefore, RARb2 and CYP26A1
expression was further analysed by noncompetitive RT–PCR. In
noncompetitive RT–PCR, we detected weak RARb2 and CYP26A1
(Figure 2A) expression in the RA-resistant breast cancer cell line,
MDA-MB-231, after treatment with aza-CdR and aRA, in a dose-
dependent manner. However, both RARb2 and CYP26A1
(Figure 2A) expression levels in treated MDA-MB-231 cells were
relatively low compared to the levels seen in RA-sensitive lung
cancer-positive control cells, Calu-6, also treated with 10mM aRA
for 3 days. CYP26A1 and RARb2 transcripts were not detected by
either competitive or noncompetitive RT–PCR in the RA-resistant
lung cancer cell line. These data indicate that DNA methylation is
one factor contributing to the repression of RARb2 and CYP26A1
transcription in MDA-MB-231 cells. However, demethylation was
insufficient to derepress transcription to a level equivalent to that
seen in a RA-sensitive cell line, for both RARb2 and CYP26A1.
Since the level of histone acetylation, and conversely deacetyla-
tion, can influence gene transcription, the effect of the histone
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Figure 1 Induction of target gene expression by RA in neuroblastoma (SH-SY5Y, BE(2)-C), lung (SK-MES-1, Calu-6) and breast (MDA-MB-231, T47D)
cancer cell lines, and neuroblastoma tissues. cDNA samples from cultured cells treated with 10mM aRA (A and D), or 13-cis-RA (B) or solvent control at
various time points, and duplicate cDNA samples from neuroblastoma arising in MYCN transgenic mice treated with 13-cis-RA or control (C) were
subjected to independent competitive RT–PCR analyses using trans-intron PCR primers, together with housekeeping gene b2M primers. An equal aliquot
of PCR product was then electrophoretically size-fractionated on a polyacrylamide gel as shown (A, B and C). Fold induction of a target gene by RA in
RA-treated samples was calculated by ascribing the ratio between the level of expression of a target gene and that of b2M as 1.0 for control-treated
samples (D).
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sdeacetylase (HDAC) inhibitor, TSA on RARb2 and CYP26A1
expression in RA-resistant lung and breast cancer cells was
investigated. Cells were treated with 0.3mM TSA in combination
with aRA (Sirchia et al, 2002) for 24h and 3 days, and analysed for
RARb2 and CYP26A1 (Figure 2B) expression. CYP26A1 and
RARb2 transcripts were detected in MDA-MB-231 cells after
treatment with TSA and aRA, yet at a much lower level than in
RA-treated Calu-6-positive control cells. CYP26A1 and RARb2
transcripts were not detected in SK-MES-1 cells. These observa-
tions together with the data from the demethylation experiments
suggest that SK-MES-1 and MDA-MB-231 cells have different
mechanisms of transcriptional repression for RARb2 and
CYP26A1, despite having a similar pattern of resistance to
RA-induced transcription.
Liganded RARb2 regulates RA-induced CYP26A1
expression
We next examined whether restoring RARb2 expression could
restore CYP26A1 transcription in RA-resistant cells. MDA-MB-231
and SK-MES-1 cells were transiently transfected with a RARb2
cDNA expression vector or empty vector control, and treated with
10mM aRA for 24h or 3 days following transfection (Figure 3A and
B). Results from a noncompetitive RT–PCR demonstrated a two-
fold increase in CYP26A1 levels in the RARb2-transfected MDA-
MB-231 cells, compared to cells transfected with the empty vector
(Figure 3A). However, the SK-MES-1 cells transfected with RARb2
did not demonstrate retinoid-inducible CYP26A1 expression
(Figure 3B).
To further examine the possibility that RARb2 directly regulated
CYP26A1 transcription in RA-sensitive cells, SH-SY5Y cells were
transiently transfected with an RARb2 cDNA expression vector or
empty vector. Reverse transcription–polymerase chain reaction
showed that RARb2 plasmid transfection upregulated RARb2 gene
expression by about eight-fold, yet CYP26A1 expression was still
undetectable, without RA treatment. In a separate experiment,
SH-SY5Y cells, Calu-6 lung and T47D breast cancer cells were
transiently transfected with scrambled siRNA or specific RARb2
siRNA and then treated with 10mM aRA for 48h. The RARb2
siRNA reduced RA-induced RARb2 transcription by about 80% in
three independent transfection experiments (Figure 3C). Retinoic
acid-induced CYP26A1 expression was downregulated by RARb2
siRNA by 36.4776.57% in SH-SY-5Y cells, 39.8575.38% in Calu-6
cells, and 2476.5% in T47D cells (Po0.001). Since both RARb2
and CYP26A1 gene expression was not detectable without aRA
treatment in all aRA-sensitive and -resistant cancer cells tested, we
did not carry out RARb2 siRNA transfection experiments without
treatment with aRA. These results indicated that RA-induced
CYP26A1 expression required retinoid liganded RARb2, in
RA-sensitive and some RA-resistant cells. Interestingly, transient
transfection of RARb2 siRNA did not repress other RA-inducible
gene expression (DUSP6, RGS16, FLNB, CRBP1, RET, PLAT).
Synchronous RA-induced expression of DUSP6 and RGS16
is required for the antiproliferative effect of RA
DUSP6 and RGS16 are both inhibitors involved in the ERK MAPK
signalling pathway, RGS16 at the level of Ras G proteins
(Buckbinder et al, 1997; Chen et al, 2001) and DUSP6 at the level
of ERK proteins (Groom et al, 1996; Sah et al, 2002; Nakagawa
et al, 2003). Since the growth inhibitory effect of RA is at least
partly due to reduction in ERK phosphorylation (Nakagawa et al,
2003), we examined the hypothesis that RA-induced proliferative
Table 3 Target gene fold induction by aRA in lung and breast cancer cells treated with 10mM aRA
Calu6 (SK-MES-1) T47D (MDA-MB-231)
Gene description GeneBank accession 1h 24h 3 days 7 days 1h 24h 3 days 7 days
RGS16 AA453774 2.1 (—) 1.4 (—) 1.6 (—) 1.4 (—) 3.2 (—) 2.7 (—) 1.7 (—) 1.4 (—)
RARb2 AA419238 1.5 (—) 7.5 (—) 8.6 (—) 9.8 (—) 1.2 (—) 12 (—) 13 (—) 22 (—)
CYP26A1 R51021 2.7 (—) 7.0 (—) 7.1 (—) 7.1 (—) 1.1 (—) 11 (—) 11 (—) 17 (—)
CRBP1 AA700832 1.1 (1.5) 1.4 (1.6) 1.5 (1.7) 2.0 (2.0) 1.5 (1.5) 2.5 (1.6) 2.7 (1.9) 5.3 (2.0)
ATP7A AA236141 1.1 (0.9) 1.1 (0.8) 0.9 (1.0) 1.3 (1.0) 1.1 (1.0) 1.1 (1.1) 0.9 (1.2) 1.3 (1.1)
DUSP6 AA630374 1.1 (1.1) 1.3 (1.1) 1.4 (1.1) 1.4 (1.3) 1.1 (0.9) 1.4 (1.0) 1.6 (1.0) 2.0 (0.9)
EGR1 AA486533 4.0 (—) 0.8 (—) 1.5 (—) 1.5 (—) — (—) — (—) — (—) — (—)
RET H24956 1.0 (0.9) 0.6 (0.8) 0.1 (1.0) 0.1 (0.9) 1.5 (—) 1.6 (—) 1.6 (—) 1.6 (—)
PLAT AA447797 1.0 (0.9) 1.0 (1.0) 0.5 (1.0) 0.5 (0.8) 0.8 (0.9) 1.5 (1.0) 1.6 (0.8) 1.5 (0.9)
FLNB AA486239 1.0 (1.0) 1.2 (1.2) 1.7 (1.1) 1.7 (1.0) 1.1 (1.1) 1.1 (1.3) 1.3 (1.0) 1.2 (1.0)
DLK1 AA576129 — (—) — (—) — (—) — (—) 1.0 (—) 0.9 (—) 0.7 (—) 0.8 (—)
SMAD3 W72201 1.0 (1.0) 1.0 (1.0) 1.0 (1.0) 1.0 (1.0) 1.1 (1.0) 1.1 (1.0) 1.0 (1.0) 1.0 (0.9)
Calu6 and T47D cells are RA sensitive, while SK-MES-1 and MDA-MB-231 are RA resistant. (—) represents undetectable by PCR.
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Figure 2 The effect of demethylation and acetylation on aRA-induced
RARb2 and CYP26A1 expression in RA-resistant cancer cells. RARb2 and
CYP26A1 expression was determined by noncompetitive RT–PCR, with
expression of housekeeping gene b2M as an internal control. (A) MDA-
MB-231 and SK-MES-1 cells were treated with control, aRA, and/or various
concentration of aza-CdR for 3 days. (B) The cells were treated with
control, aRA, and/or 0.3mM TSA for 3 days. The last lane of each gel
(þVE) contained a positive control from RA-sensitive Calu-6 cells treated
with 10mM aRA for 3 days.
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sarrest was dependent on increased expression of DUSP6 or RGS16.
Three DUSP6 and three RGS16 siRNA duplexes were in vitro
transcribed, and transfected into SH-SY5Y cells, followed by 10mM
aRA treatment. Competitive RT–PCR showed that the DUSP6
siRNA targeting AAGTGCGGAATTGGTTAATAC, and the RGS16
siRNA targeting AACAAGGCAGAAAAGGATCCT, were the most
efficient siRNAs at reducing the expression of each gene
(Figure 4A). These siRNAs were, therefore, chosen in all further
experiments for protein and cell proliferation studies. As shown
in Figure 4B, 48h of treatment with 10mm aRA induced
RGS16 protein by two-fold, and DUSP6 protein more drama-
tically from only just detectable, compared with solvent control.
At the same time point, RGS16 siRNAs effectively counteracted
RA-responsive RGS16 overexpression, while DUSP6 siRNA
abolished RA-responsive DUSP6 induction.
To determine the roles of DUSP6 and RGS16 in MAPK ERK
dephosphorylation, cell lysates from SH-SY5Y cells transfected
with scrambled, DUSP6, and/or RGS16 siRNAs with or without
10mM aRA treatment for 60h were subjected to ERK and
phosphorylated ERK immunoblot. Without aRA intervention,
DUSP6 and/or RGS16 siRNA transfection did not have an effect
on ERK phosphorylation. Compared with scrambled siRNA
counterparts, DUSP6 siRNA increased ERK phosphorylation by
about 2.5-fold, while RGS16 siRNA induced ERK phosphorylation
by 1.4-fold (Figure 4C). When cells were cotransfected with siRNAs
against DUSP6 and RGS16, we observed an additive effect on ERK
phosphorylation of a further 1.6-fold compared with DUSP siRNA
alone, or four-fold compared with scrambled siRNA mixture
(Figure 4C). All siRNAs did not show any effect on total ERK
protein expression.
In the cell proliferation studies, BrdU incorporation by SH-SY5Y
cells transfected with scrambled siRNA was decreased after 60h of
aRA treatment, compared with solvent control. We did not observe
a significant effect of transfection of DUSP6 siRNA or RGS16
siRNA alone, compared with scrambled siRNA, on BrdU uptake
(Figure 4D). In contrast, transfection of a combination of DUSP6
and RGS16 siRNAs reduced the proportion of BrdU-negative cells
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Figure 3 Liganded RARb2 modulates CYP26A1 expression. RARb2
gene expression was analysed with the standard competitive RT–PCR, and
CYP26A1 expression was analysed by competitive RT–PCR in RA-
sensitive SH-SY5Y, Calu-6, and T47D cells and noncompetitive RT–PCR in
RA-resistant cells, with housekeeping gene b2M as an internal control. (A,
B) CYP26A1 transcription was determined in MDA-MB-231 (A) or SK-
MES-1 cells (B) transiently transfected with RARb2 cDNA plasmid or
vector plasmid and treated with control or 10mM aRA for 24h (Lanes 2
and 5) or 3 days (lanes 3 and 6). Last lane in (B) contained the positive
control from Calu-6 cells treated with 10mM aRA for 3 days. (C) RARb2
and CYP26A1 expression was analysed in SH-SY5Y, Calu-6, and T-47D
cells transfected with scramble siRNA or RARb2 siRNA and treated with
10mM aRA for 48h.
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Figure 4 Synchronous expression of both DUSP6 and RGS16
contributed to RA-induced growth inhibition. (A) DUSP6 and RGS16
gene expression was analysed with competitive RT–PCR with the
housekeeping gene b2M as an internal control with samples from SH-
SY5Y cells transfected with DUSP6 or RGS16 siRNA or scrambled siRNA
and treated with 10mM aRA for 48h. *Indicates the siRNAs of choice for
protein and functional studies. (B) DUSP6 and RGS16 protein was
analysed by Western blot with samples from SH-SY5Y cells transfected
with scrambled siRNA, DUSP6, or RGS16 siRNA and treated with 10mM
aRA or control solvent for 48h. b-Actin protein was used as a loading
control. (C) Phosphorylated ERK1/2 was analysed by Western blot with
samples from SH-SY5Y cells transfected with scrambled, DUSP6, RGS16
siRNA, or siRNA combinations and treated with 10mM aRA for 60h. Total
ERK1/2 protein was used as a loading control. (D) BrdU incorporation into
proliferating cells was analysed in SH-SY5Y cells after transfection with
scrambled or target gene siRNAs plus treatment with 10mM aRA for 64h.
BrdU-positive cells treated with vehicle solvent and transfected with
scrambled siRNA were artificially set as 100%. Error bar represented
standard error. **Indicated statistical significant difference (Po0.05).
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sdue to aRA treatment, and reduced the effect of aRA on BrdU
incorporation by more than 40% (Po0.05). These findings
indicated that combined inhibition of the MAPK at two levels
mediated the retinoid effects on cell proliferation. As DUSP6
protein was hardly detectable without RA treatment, the effect of
siRNA in the cell proliferation assay was not carried out without
RA treatment.
DISCUSSION
In this study, we used cDNA microarray to identify 31 RA-
regulated target genes shared by two RA-sensitive neuroblastoma
cells lines, and then evaluated the relevance of RA-induced
changes in target gene expression to the RA anticancer effect.
Our data suggest that RA-induced changes in the expression of
RARb2, CYP26A1, CRBP1, RGS16, DUSP6, and EGR1 may be
necessary for the retinoid anticancer signal in neuroblastoma,
breast and/or lung cancer cells. However, we found little evidence
for a direct signalling relationship among these genes, except that
RA-induced CYP26A1 expression is partly modulated by RARb2.
Our data showed clearly that exogenous overexpression of RARb2
did not induce CYP26A1 expression in the absence of RA ligand,
even in RA-sensitive cancer cells. However, forced overexpression
of RARb2 activated CYP26A1 transcription in RA-resistant breast
cancer cells when the RARb2 ligand, RA, was added. Consistently,
knocking down of RA-induced RARb2 expression partly blocked
RA-induced CYP26A1 expression across RA-sensitive neuroblas-
toma, lung and breast cancer cells. This inter-relationship is in
agreement with earlier studies, which showed that exogenous
RARb2 overexpression in RA-resistant HCT-116 colon cancer cells
partially restored RA-induced CYP26A1 expression (Sonneveld
et al, 1998). Our data indicate that the close link between RARb2
and CYP26A1 expression patterns may be explained by the
dependence of CYP26A1 expression on liganded RARb2. Addi-
tionally, we found that 13-cis-RA only marginally upregulated
CYP26A1 expression in neuroblastoma tissues in vivo, while
inducing RARb2 expression to a similar extent as in vitro. This
observation suggests that there may be other mechanisms limiting
the extent to which 13-cis-RA liganded RARb2 can induce
CYP26A1 in vivo.
DNA methylation and histone deacetylation of the RARb2 gene
promoter region have been proposed to result in RARb2 silencing
and RA resistance (Sirchia et al, 2002; Suh et al, 2002). Our study
confirmed these findings and found, for the first time, that both
DNA methylation and HDAC contribute to CYP26A1 silencing in
MDA-MB-231 cells. In contrast, neither DNA demethylation nor
the HDAC inhibitor had any effect on RA-induced CYP26A1 or
RARb2 expression in SK-MES-1 cells. The RARb2 gene promoter
has been shown to be hypermethylated and hypoacetylated in
SK-MES-1 cells, and to be resistant to DNA demethylation and
histone acetylation (Suh et al, 2002). The CYP26A1 gene promoter
may also have been resistant to demethylating or acetylating agents
due to as yet undefined mechanisms.
This study, for the first time, identified DUSP6 and RGS16 as
novel RA target genes, and found that synchronous knock down of
RA-induced DUSP6 and RGS16 expression synergistically/addi-
tively increased MAPK ERK phosphorylation and partly blocked
RA-induced growth inhibition, although decreased expression of
either protein alone was insufficient to effect cell prolifera-
tion. DUSP6 encodes a dual-specificity phosphatase specific for
ERK (Groom et al, 1996), a key effector MAPK involved in the
RAS-GTP signal transduction pathway (Hunter, 1995; Becker,
2004). DUSP6 dephosphorylates activated ERK and blocks the
growth-stimulatory signals (Furukawa et al, 2003; Furukawa and
Horii, 2004). RGS16, on the other hand, acts as a mechanism for
p53 to exert cellular growth control and acts as a negative feedback
regulator in response to mitogenic signals (Buckbinder et al, 1997).
RGS16 inhibits ERK activation upstream of the RAS-RAF-MEK-
ERK pathway by enhancing GTPase-activating protein function
and inactivating RAS-GTP (Buckbinder et al, 1997; Chen et al,
2001). Various inhibitors of RAS-RAF-MEK-ERK signalling path-
way have been proven to inhibit cancer cell growth and survival,
and are already in phase II clinical trials for the treatment of
various cancers (Sebolt-Leopold and Herrera, 2004). DUSP6 and
RGS16 transcriptional upregulation inhibits tumour cell prolifera-
tion and ERK phosphorylation, and serves as a negative regulatory
mechanism to prevent further ERK phosphorylation. Our data
therefore indicates that RA-induced upregulation of DUSP6 and
RGS16 inhibits tumour cell proliferation, through acting on two
levels of RAS-RAF-MEK-ERK signalling pathway and eventually
synergistically reducing ERK phosphorylation.
In conclusion, we have demonstrated both classical and novel
mechanisms by which RA-regulated target gene expression
patterns may relate to the retinoid anticancer signal. Our findings
have confirmed the importance of previously recognised signalling
molecules such as RARb2, and have identified novel roles for
MAPK signal inhibitory proteins DUSP6 and RGS16 in mediating
the retinoid anticancer effect.
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